Table 3. Demographic and clinical data for the patients according to liver fibrosis.
| n | F0–F2 (n = 75) | F3–F4 (n = 97) | P-value | |
| Age | 172 | 43 (33–63) | 46 (39–65) | 0.005 |
| Gender (male) | 172 | 0.003 | ||
| Male | 50 (67) | 83 (86) | ||
| Female | 25 (33) | 14 (14) | ||
| Geographic origin | 160 | 0.76 | ||
| Europe | 49 (69) | 66 (75) | _ | |
| North Africa | 14 (20) | 17 (19) | _ | |
| Sub-Saharan Africa | 5 (7) | 3 (3) | ||
| Other | 3 (4) | 3 (3) | ||
| Body-mass index | 167 | 22.2 (17.4–32.2) | 22.4 (13.9–37.0) | 0.967 |
| Insulin resistance | 138 | 0.01 | ||
| HOMA <3.8 | 49 (82) | 48 (62) | ||
| HOMA ≥3.8 | 11 (18) | 30 (38) | ||
| Alcohol consumption | 171 | 0.019 | ||
| Never | 17 (23) | 15 (16) | ||
| Ongoing | 18 (24) | 43 (45) | ||
| Past | 40 (53) | 38 (39) | ||
| Age at infection | ||||
| HCV infection | 172 | 21 (14–43) | 21 (13–43) | 0.693 |
| HIV infection | 171 | 28 (10–49) | 29 (19–59) | 0.506 |
| Duration of infection | ||||
| HCV infection (years) | 22 (1–37) | 24 (1–42) | 0.004 | |
| HIV infection (years) | 18 (1–23) | 18 (1–24) | 0.11 | |
| Source of HCV infection | 0.02 | |||
| IVDU | 55 (73) | 76 (87) | ||
| Other | 20 (27) | 11 (13) | ||
| Source of HIV infection | 171 | 0.010 | ||
| IVDU | 49 (66) | 81 (84) | ||
| Other | 25 (34) | 16 (16) | ||
| CDC clinical stage | 172 | 0.423 | ||
| A | 40 (53) | 42 (43) | ||
| B | 18 (24) | 29 (30) | ||
| C | 17 (23) | 26 (27) | ||
| Plasma HIV RNA concentration | 0.874 | |||
| Undetectable (<50 copies/mL) | 42 (68) | 60 (69) | ||
| Detectable (≥50 copies/mL) | 20 (32) | 27 (31) | ||
| HIV RNA concentration (when detectable) (log10) | 3.1 (1.8–4.9) | 3.1 (1.7–5.8) | 0.855 | |
| CD4-cell count at inclusion | 171 | 396 (55–1878) | 356 (48–1185) | 0.032 |
| Nadir CD4-cell count | 153 | 185 (4–520) | 110 (1–480) | 0.002 |
| HIV tropism | 172 | 0.685 | ||
| (CCR5-using virus) | 52 (69) | 70 (72) | ||
| (CXCR4-using virus) | 23 (31) | 27 (28) | ||
| ART at inclusion | 172 | 0.516 | ||
| Naïve | 4 (5) | 3 (3) | ||
| Pre-treated patients | 5 (7) | 4 (4) | ||
| Ongoing treatment | 66 (88) | 90 (93) | ||
| Class of ART at inclusion | 172 | |||
| PI | 47 (63) | 64 (66) | 0.653 | |
| NNRTI | 17 (23) | 18 (19) | 0.507 | |
| NRTI | 64 (85) | 85 (88) | 0.661 | |
| Cumulative duration under ART before inclusion (months) | 165 | 108.1 (0.9–192.1) | 120.4 (4.0–243.7) | 0.024 |
| Cumulative duration under PI before inclusion (months) | 144 | 50.3 (0.9–141.7) | 67.6 (1.1–199.3) | 0.121 |
| Cumulative duration of NNRTI before inclusion (months) | 109 | 28.2 (0.3–118.9) | 20.3 (0.3–117.6) | 0.724 |
| Cumulative duration of NRTI before inclusion (months) | 165 | 105.0 (0.9–192.1) | 120.4 (4.0–243.7) | 0.027 |
| HCV genotype | 171 | 0.064 | ||
| 1 | 47 (63) | 61 (63) | ||
| 2 | 0 (-) | 2 (2) | ||
| 3 | 11 (15) | 24 (25) | ||
| 4 | 16 (22) | 10 (10) | ||
| Plasma HCV RNA concentration (log10; UI/mL) | 145 | 6.3 (1.6–7.8) | 6.1 (3.3–7.8) | 0.173 |
| Steatosis | 112 | 0.725 | ||
| ≤10% | 53 (72) | 26 (68) | ||
| >10% | 21 (28) | 12 (32) | ||
Abbreviations: ART: antiretroviral therapy; CDC: Centers for Disease Control; HOMA: homeostasis model assessment of insulin resistance score; PI: protease inhibitors; NNRTI: non-nucleoside reverse-transcriptase inhibitors; NRTI: nucleoside reverse-transcriptase inhibitors; IQR: inter-quartile range; IVDU: intravenous drug user.